Verition Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-898
| Closed | -$297K | – | 2075 |
|
|
2026
Q1 | $297K | Sell |
898
-3,107
| -78% | -$1.06M | ﹤0.01% | 1781 |
|
|
2025
Q4 | $1.59M | Sell |
4,005
-13,028
| -76% | -$5.77M | 0.01% | 1803 |
|
|
2025
Q3 | $7.77M | Buy |
17,033
+11,330
| +199% | +$4.61M | 0.03% | 707 |
|
|
2025
Q2 | $1.86M | Sell |
5,703
-5,076
| -47% | -$1.4M | 0.01% | 2014 |
|
|
2025
Q1 | $2.91M | Buy |
10,779
+7,876
| +271% | +$2.02M | 0.01% | 1294 |
|
|
2024
Q4 | $683K | Sell |
2,903
-14,565
| -83% | -$3.83M | ﹤0.01% | 2286 |
|
|
2024
Q3 | $4.8M | Buy |
17,468
+10,053
| +136% | +$2.62M | 0.02% | 875 |
|
|
2024
Q2 | $1.8M | Buy |
7,415
+3,019
| +69% | +$477K | 0.01% | 1335 |
|
|
2024
Q1 | $657K | Buy |
+4,396
| New | +$733K | ﹤0.01% | 1860 |
|
|
2023
Q4 | – | Sell |
-1,391
| Closed | -$246K | – | 2305 |
|
|
2023
Q3 | $246K | Buy |
+1,391
| New | +$265K | ﹤0.01% | 1853 |
|
|
2022
Q4 | – | Sell |
-4,827
| Closed | -$966K | – | 2099 |
|
|
2022
Q3 | $966K | Buy |
+4,827
| New | +$921K | 0.01% | 1430 |
|
|
2022
Q2 | – | Sell |
-2,404
| Closed | -$393K | – | 2310 |
|
|
2022
Q1 | $393K | Sell |
2,404
-4,982
| -67% | -$759K | ﹤0.01% | 2039 |
|
|
2021
Q4 | $1.25M | Buy |
7,386
+6,318
| +592% | +$1.17M | 0.01% | 1151 |
|
|
2021
Q3 | $202K | Buy |
+1,068
| New | +$200K | ﹤0.01% | 1612 |
|
|
2020
Q3 | – | Sell |
-1,743
| Closed | -$258K | – | 1039 |
|
|
2020
Q2 | $258K | Buy |
+1,743
| New | +$235K | 0.01% | 859 |
|
|
2020
Q1 | – | Sell |
-5,304
| Closed | -$611K | – | 587 |
|
|
2019
Q4 | $611K | Buy |
+5,304
| New | +$529K | 0.01% | 600 |
|
|
2019
Q3 | – | Sell |
-12,222
| Closed | -$887K | – | 1024 |
|
|
2019
Q2 | $887K | Buy |
+12,222
| New | +$938K | 0.02% | 476 |
|
|
2018
Q3 | – | Sell |
-4,436
| Closed | -$437K | – | 1226 |
|
|
2018
Q2 | $437K | Sell |
4,436
-1,017
| -19% | -$101K | 0.03% | 734 |
|
|
2018
Q1 | $649K | Buy |
+5,453
| New | +$703K | 0.05% | 534 |
|
|
2017
Q3 | – | Sell |
-13,296
| Closed | -$1.06M | – | 1142 |
|
|
2017
Q2 | $1.06M | Buy |
+13,296
| New | +$850K | 0.1% | 188 |
|
|
2015
Q2 | – | Sell |
-5,495
| Closed | -$574K | – | 603 |
|
|
2015
Q1 | $574K | Buy |
5,495
+2,691
| +96% | +$273K | 0.07% | 91 |
|
|
2014
Q4 | $272K | Sell |
2,804
-918
| -25% | -$85K | 0.06% | 158 |
|
|
2014
Q3 | $291K | Buy |
+3,722
| New | +$240K | 0.04% | 409 |
|
Other funds holding ALNY
Verition Fund Management's ALNY Position: Q2 2026 in Review
Verition Fund Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 898 shares — an estimated $297K sold.
Verition Fund Management first reported a position in ALNY in Q3 2014 and held it in 23 quarters. The position peaked at $7.77M in Q3 2025. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Verition Fund Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Verition Fund Management sold 898 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $297K.
- Verition Fund Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 23 quarters.
- Verition Fund Management's Alnylam Pharmaceuticals position peaked at $7.77M in Q3 2025.
- 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.